Fluidigm said today that the Munich Leukemia Laboratory has purchased Access Array and EP1 systems to use with Roche's 454 GS FLX and GS Junior sequencers.

Fluidigm's Access Array will enable researchers at MLL to perform high-throughput targeted deep resequencing analyses; while the EP1 system will be used for rare mutation detection studies and minimal residual disease investigations, Fluidigm said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.